1. 1) Li W., Escarpe P. A., Eisenberg E. J., Cundy K. C., Sweet C., Jakeman K. J., Merson J., Lew W., Williams M., Zhang L., Kim C. U., Bischofberger N., Chen M. S., Mendel D. B., Antimicrob. Agents Chemother., 42, 647—653 (1998).
2. 2) Sidwell R. W., Huffman J. H., Barnard D. L., Bailey K. W., Wong M. H., Morrison A., Syndergaard T., Kim C. U., Antiviral Res., 37, 107—120 (1998).
3. 3) Roche Pharma Japan Co., Interview Form (Tamiflu Capsule 75 and Dry Syrup 3%), (in Japanese) (2002).
4. 4) Roche Pharma Japan Co., Tamiflu NDA data summary, Documents on absorption, distribution, metabolism and excretion (in Japanese), Available from WEB page of Japan Pharmacists Education Center, http://www.jpec.or.jp/contents/c01/link.html (2000).
5. 5) Nicholson K. G., Aoki F. Y., Osterhous A. D., Trottier S., Carewicz O., Mercier C. H., Rode A., Kinnersley N., Ward P., Lancet, 355, 1845—1850 (2000).